Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma.
暂无分享,去创建一个
P. Marsden | J. Radford | P. Schleyer | M. O'Doherty | S. Barrington | P. Johnson | N. Mikhaeel | W. Qian | J. Mackewn | P. Mouncey | P. Patrick | B. Popova | Wendi Qian | John Radford | Sally F Barrington | Paul Schleyer | Paul Marsden | Wendi Qian | Pip Patrick | Bilyana Popova | Peter Johnson | Michael O'Doherty | S. Barrington
[1] J. Radford,et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[2] W. Oyen,et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[3] R. Boellaard,et al. Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies , 2009, Journal of Nuclear Medicine.
[4] Joel S. Karp,et al. Qualification of PET Scanners for Use in Multicenter Cancer Clinical Trials: The American College of Radiology Imaging Network Experience , 2009, Journal of Nuclear Medicine.
[5] Martin Hutchings,et al. PET/CT for Therapy Response Assessment in Lymphoma , 2009, Journal of Nuclear Medicine.
[6] A. Rahmouni,et al. Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy , 2009, Journal of Nuclear Medicine.
[7] Michel Meignan,et al. Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.
[8] Claude Nahmias,et al. Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors , 2008, Journal of Nuclear Medicine.
[9] W. Oyen,et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[10] J. Leonard,et al. FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma , 2008, Leukemia & lymphoma.
[11] Emmanuel Itti,et al. Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis , 2007, Journal of Nuclear Medicine.
[12] F. d'Amore,et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Klemens Scheidhauer,et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] N. Mikhaeel,et al. Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[15] Joel Karp,et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] A. Levis,et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. , 2006, Haematologica.
[17] Martin Hutchings,et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.
[18] M. O'Doherty,et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] M. Blaufox,et al. A metaanalysis of 18F‐2‐deoxy‐2‐fluoro‐D‐glucose positron emission tomography in the staging and restaging of patients with lymphoma , 2005, Cancer.
[20] N. Mikhaeel,et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] S. Holm,et al. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[22] Patrick Dupont,et al. [18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction? , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[23] M. O'Doherty,et al. Does diabetes affect [18F]FDG standardised uptake values in lung cancer? , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[24] Lilli Geworski,et al. Multicenter comparison of calibration and cross calibration of PET scanners. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] Paul K. Marsden,et al. Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer , 2001, European Journal of Nuclear Medicine.
[26] Yuan-Hwa Chou,et al. A PET study of [11C]β-CIT-FE binding to the dopamine transporter in the monkey and human brain , 2000 .
[27] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[28] P. Marsden,et al. A PET study of 18FDG uptake in soft tissue masses , 1999, European Journal of Nuclear Medicine.
[29] S. Evans,et al. Recommended Standards For The Routine Performance Testing of Diagnostic X-Ray Imaging Systems , 1998 .
[30] J. D. van der Walt,et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. , 1998, Blood.
[31] J. Keyes. SUV: standard uptake or silly useless value? , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.